Doximity, Inc., also known as DOCS, is a leading digital platform for medical professionals in the United States. The company was founded in 2011, and its headquarters is located in San Francisco. Doximity's mission is to connect healthcare professionals and make them more successful and effective through innovative technology and user-friendly tools.
The heart of Doximity's service is its online network that allows doctors, nurses, pharmacists, and other healthcare professionals to connect with each other, share crucial information, and collaborate on necessary cases. The network features doctor profiles, hospital affiliation details, medical school credentials, and more. It is currently being used by over a million healthcare professionals in the U.S, including over 80% of physicians, marking it as the largest professional network for clinicians in the country.
The unique selling proposition of Doximity is its ability to save time and enhance the ease and quality of communication among healthcare professionals. This is particularly important in an industry where prompt and detailed communication can make a significant difference in patient outcomes.
Apart from networking, Doximity also offers a suite of other tools and services. These include Doximity Dialer, a telemedicine product that facilitates secure video calls between doctors and patients. Also, there is Doximity Epocrates, a mobile drug reference resource that provides quick access to important drug information and interaction checkers.
The company also provides a platform for continuing medical education, open job postings in the healthcare sector, clinical news updates, and research papers. Around 600,000 hours of medical content are consumed on Doximity's platform each month, showing its widespread use and the trust the medical community puts in the platform.
Doximity went public on June 24, 2021, with an initial public offering (IPO) on the New York Stock Exchange under the ticker symbol DOCS. The company's IPO was hailed as a significant success, with the shares surging considerably on the opening day.
Overall, Doximity, Inc. is not just a networking site, but a thriving ecosystem of tools and services designed to address the diverse needs of healthcare professionals. Its potential for growth is large, given the rapid evolution of technology in healthcare and the increasing reliance on remote and digital tools for medical practice. Despite being a young company, Doximity has already made a significant impact in the medical field and is well-positioned to continue doing so in the future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Robbins LLP reminds Doximity, Inc. (NYSE: DOCS) investors of a class action lawsuit filed against the company. The lawsuit alleges that Doximity overstated the impact of its Newsfeed on revenue growth and failed to disclose that it was losing market share due to competitors with more favorable pricing. Investors who suffered losses during the Class Period (August 8, 2024, to May 13, 2026) are encouraged to contact Robbins LLP before the November 16, 2026, lead plaintiff deadline.
Rosen Law Firm is encouraging investors of Doximity, Inc. (NYSE: DOCS) who experienced losses exceeding $100,000 to join a securities class action lawsuit. The deadline for investors to serve as lead plaintiff is November 16, 2026. The lawsuit alleges that Doximity overstated the impact of its Newsfeed on revenue growth and was losing market share due to less favorable engagement models.
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Doximity, Inc. (NYSE:DOCS) on behalf of investors who purchased common stock between August 8, 2024, and May 13, 2026. The lawsuit alleges that Doximity made materially misleading statements regarding its competitive position and revenue growth, leading to significant stock declines. Co-founder and Chief Strategy Officer Nate Gross is named as an individual defendant, with investors having until November 16, 2026, to seek appointment as lead plaintiff.